Citing the IRB's approval of Biomoda's protocol as a significant step forward, Biomoda President and CEO John Cousins said, "This not only launches our Phase I clinical study, but it also puts us in a position to have a meaningful impact on people's lives today. Our initial study is directed at military veterans who are at high risk for developing lung cancer. If our screening reveals early-stage cancer in one of our volunteers, that person's chance of being alive five years from now goes from 15 percent to 80 percent, all because of early diagnosis and treatment." It is our intent in this pilot program to identify five to ten such cases and have a dramatic impact on saving lives here in New Mexico now.
Monday, March 16, 2009
Biomoda Approved To Begin Screening Veterans For Lung Cancer
Biomoda, Inc. (OTCBB: BMOD), a medical diagnostics company based in Albuquerque, received approval from an independent Institutional Review Board (IRB) to begin Phase I clinical trials of its cytology-based screening technology for early detection of cancer.
Citing the IRB's approval of Biomoda's protocol as a significant step forward, Biomoda President and CEO John Cousins said, "This not only launches our Phase I clinical study, but it also puts us in a position to have a meaningful impact on people's lives today. Our initial study is directed at military veterans who are at high risk for developing lung cancer. If our screening reveals early-stage cancer in one of our volunteers, that person's chance of being alive five years from now goes from 15 percent to 80 percent, all because of early diagnosis and treatment." It is our intent in this pilot program to identify five to ten such cases and have a dramatic impact on saving lives here in New Mexico now.
Citing the IRB's approval of Biomoda's protocol as a significant step forward, Biomoda President and CEO John Cousins said, "This not only launches our Phase I clinical study, but it also puts us in a position to have a meaningful impact on people's lives today. Our initial study is directed at military veterans who are at high risk for developing lung cancer. If our screening reveals early-stage cancer in one of our volunteers, that person's chance of being alive five years from now goes from 15 percent to 80 percent, all because of early diagnosis and treatment." It is our intent in this pilot program to identify five to ten such cases and have a dramatic impact on saving lives here in New Mexico now.
Subscribe to:
Post Comments (Atom)
Kick Butts Today!
No comments:
Post a Comment